A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

NCT01149421 on ClinicalTrials.gov · last registry update 2015-02-02

An unusually large phase 2: 755 participants, more than double the 110 typical for the stage. The sponsor logged completion for September 2011. Primary outcome, as filed: Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP). dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 755
Started: 2010-06
Primary completion: 2011-09 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.